Dr Topalian speaks with ecancer at AACR 2017 about the combination of ipilimumab and nivolumab for advanced melanoma.
The results were presented at the conference by Dr James Larkin, and Dr Topalian comments on the response rates and overall survival in the combination.
She considers the prospective value of BRAF and PD-1 biomarkers, and notes a significant increase in trial discontinuation due to adverse events.
